PL355355A1 - Method of obtaining bacteriophage strain with increased affinity for eukaryotic cells, agents containing it and the use of bacteriophages - Google Patents

Method of obtaining bacteriophage strain with increased affinity for eukaryotic cells, agents containing it and the use of bacteriophages

Info

Publication number
PL355355A1
PL355355A1 PL02355355A PL35535502A PL355355A1 PL 355355 A1 PL355355 A1 PL 355355A1 PL 02355355 A PL02355355 A PL 02355355A PL 35535502 A PL35535502 A PL 35535502A PL 355355 A1 PL355355 A1 PL 355355A1
Authority
PL
Poland
Prior art keywords
bacteriophages
eukaryotic cells
agents containing
increased affinity
bacteriophage strain
Prior art date
Application number
PL02355355A
Other languages
Polish (pl)
Other versions
PL195815B1 (en
Inventor
Krystyna Dąbrowska
Andrzej Górski
Anna Nasulewicz
Adam Opolski
Joanna Wietrzyk
Original Assignee
Instytut Immunologii i Terapii Doświadczalnej PAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Immunologii i Terapii Doświadczalnej PAN filed Critical Instytut Immunologii i Terapii Doświadczalnej PAN
Priority to PL355355A priority Critical patent/PL195815B1/en
Priority to PCT/PL2003/000075 priority patent/WO2004013317A1/en
Priority to AU2003272158A priority patent/AU2003272158A1/en
Publication of PL355355A1 publication Critical patent/PL355355A1/en
Publication of PL195815B1 publication Critical patent/PL195815B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL355355A 2002-08-05 2002-08-05 Method of receiving bacteriofage strain featuring increased affinity for eucariotic cells, compounds containing such bacteriofage strain and bacteriofage application PL195815B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL355355A PL195815B1 (en) 2002-08-05 2002-08-05 Method of receiving bacteriofage strain featuring increased affinity for eucariotic cells, compounds containing such bacteriofage strain and bacteriofage application
PCT/PL2003/000075 WO2004013317A1 (en) 2002-08-05 2003-08-05 A method of obtaining a bacteriophage strain of increased affinity to eukaryotic cells, preparations containing it, and applications of bacteriophages
AU2003272158A AU2003272158A1 (en) 2002-08-05 2003-08-05 A method of obtaining a bacteriophage strain of increased affinity to eukaryotic cells, preparations containing it, and applications of bacteriophages

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL355355A PL195815B1 (en) 2002-08-05 2002-08-05 Method of receiving bacteriofage strain featuring increased affinity for eucariotic cells, compounds containing such bacteriofage strain and bacteriofage application

Publications (2)

Publication Number Publication Date
PL355355A1 true PL355355A1 (en) 2004-02-09
PL195815B1 PL195815B1 (en) 2007-10-31

Family

ID=31492971

Family Applications (1)

Application Number Title Priority Date Filing Date
PL355355A PL195815B1 (en) 2002-08-05 2002-08-05 Method of receiving bacteriofage strain featuring increased affinity for eucariotic cells, compounds containing such bacteriofage strain and bacteriofage application

Country Status (3)

Country Link
AU (1) AU2003272158A1 (en)
PL (1) PL195815B1 (en)
WO (1) WO2004013317A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011162627A1 (en) 2010-06-20 2011-12-29 Instytut Immunologii i Terapii Doświadczalnej PAN A method of producing bacteriophages
WO2014195871A1 (en) 2013-06-03 2014-12-11 Warszawski Uniwersytet Medyczny Use of bacteriophages

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618886A1 (en) * 2004-07-20 2006-01-25 Fonds zur Förderung der Forschung auf dem Gebiet der molekularen Virologie und Gentherapie Bacteriophage and prophage proteins in cancer gene therapy
WO2006066224A2 (en) * 2004-12-14 2006-06-22 Yale University Virulence targeted antibiotics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736388A (en) * 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011162627A1 (en) 2010-06-20 2011-12-29 Instytut Immunologii i Terapii Doświadczalnej PAN A method of producing bacteriophages
WO2014195871A1 (en) 2013-06-03 2014-12-11 Warszawski Uniwersytet Medyczny Use of bacteriophages

Also Published As

Publication number Publication date
WO2004013317A1 (en) 2004-02-12
AU2003272158A1 (en) 2004-02-23
PL195815B1 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
FI20011642A7 (en) Waterproof and temperature-controlled tank with improved longitudinal cross-section of solid angles
DE60331092D1 (en) HYDROGEN AND OLEOPHOBIC AGENTS
IL162266A (en) Substituted 2-thio-3,5-dicyano-4- phenyl-6-aminopyridines and the use of the same
DE60329502D1 (en) COMBINED OXYGEN SATURATION AND TEMPERATURE GAUGES
BRPI0312331A2 (en) hyaluronic acid compositions and methods of use.
NO20055568D0 (en) Substituted 1,4-diazepines and uses thereof
ATE458717T1 (en) BETA-AMINO-ALPHA-CYANOACRYLATES AND THEIR USE AS HERBICIDES
EP1377611A4 (en) MUTINES OF THE HYPOXIC INDUCIBLE FACTOR ALPHA AND METHOD OF USE THEREOF
ID28997A (en) SENSE OF USE, AND THE PROCESS OF MAKING
DE60106954D1 (en) Resorcinol DERIVATIVES
DE60211810D1 (en) PYROLYSEROHR AND THIS USE PYROLYSIS PROCESS
ATE400571T1 (en) PYRROLYL THIAZOLES AND THEIR USE AS INVERSE AGONISTS OF THE CB 1 RECEPTOR
DK1276476T3 (en) Use of bradycardic agents in the treatment of cardiovascular diseases associated with hypertrophy, as well as novel drug combinations
NO20044398L (en) Photocatalysts containing titanium oxide, as well as the process and use thereof
PL364600A1 (en) The method of producing hydrogen and its application
DE60318139D1 (en) Isolator and arrangement configuration
CL2004000877A1 (en) PHARMACEUTICAL COMBINATION THAT INCLUDES 8A) MELATONIN AND MELATONINE AGONISTS, AND NICOTINE AND NICOTINE RECEIVING AGONISTS; PHARMACEUTICAL KIT, AND; USE IN THE TREATMENT OF INSOMNIUM, COGNITIVE DIFFICULTIES AND MEMORY DIFFICULTIES; FARMACEU KIT
AU2003274905A8 (en) Recombinant double-stranded rna phage, and use of the same
TW200633948A (en) Composites and methods for the manufacture and use thereof
IS7334A (en) Benzothiazole and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors
FI20031472A0 (en) The method of the network converter and the network converter
CY1108053T1 (en) UNION OF CYAMEMAZINE AND A FORMULATED NEUROLIPTIC
BR0316544A (en) Calcally Compounds
AU2003297269A8 (en) Bacteriophage having modified holin and uses thereof
AU2003272158A1 (en) A method of obtaining a bacteriophage strain of increased affinity to eukaryotic cells, preparations containing it, and applications of bacteriophages

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20130805